von Kalle C, Glimm H, Schulz G, Mertelsmann R, Henschler R
University of Freiberg, Germany.
Curr Opin Hematol. 1998 Jan;5(1):79-86. doi: 10.1097/00062752-199801000-00013.
The possibility of maintaining, manipulating, and expanding human hematopoietic stem cells in ex vivo culture could help to provide patients with autologous and allogeneic stem cell transplants improved in purity and performance and could offer access to gene therapy of the hematopoietic system. Recent advances in the ex vivo culture of immature human hematopoietic progenitor cells and human hematopoietic stem cells have led to experimental evidence for the qualitative and quantitative maintenance and possible numerical expansion of hematopoietic stem cells in ex vivo culture, making ex vivo graft engineering a realistic possibility. This review summarizes recent developments in the field, their regulatory implications and their application in hematopoietic gene therapy.
在体外培养中维持、操控和扩增人类造血干细胞的可能性，有助于为患者提供纯度和性能均得到改善的自体和异体干细胞移植，并可能为造血系统的基因治疗提供途径。未成熟人类造血祖细胞和人类造血干细胞体外培养的最新进展，已产生实验证据表明造血干细胞在体外培养中可实现定性和定量维持以及可能的数量扩增，使得体外移植物工程成为一种现实的可能性。本综述总结了该领域的最新进展、其监管意义及其在造血基因治疗中的应用。
